• Profile
Close

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial

Arthritis & Rheumatology Apr 20, 2019

Kitas GD, et al. - Given a higher risk of cardiovascular event (CVE) in correlation with rheumatoid arthritis (RA), researchers examined the primary preventive value of atorvastatin vs placebo for CVE in RA patients. They performed a randomized, double-blind, placebo-controlled trial including 3002 patients aged >50 years or with RA duration >10 years; without clinical atherosclerosis, diabetes, or myopathy. Atorvastatin 40mg daily or matching placebo was administered to the patients. Outcomes support atorvastatin 40mg daily as safe in patients with RA; it resulted in significantly greater reduction of LDLc than placebo. In line with the Cholesterol Treatment Trialists’ Collaboration meta-analysis of statin effects in other populations, they identified 40% (adjusted) CVE risk reduction.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay